一种二硫环肽化合物
Search documents
万邦德股价下跌2.12% 子公司获二硫环肽化合物发明专利
Jin Rong Jie· 2025-08-21 16:18
Group 1 - The stock price of Wanbangde as of August 21, 2025, is 7.86 yuan, down 0.17 yuan from the previous trading day's closing price, representing a decline of 2.12% [1] - The company operates in the chemical pharmaceutical sector, with its main business segments being pharmaceutical manufacturing (48.76%), specialized equipment manufacturing and services (32.21%), and pharmaceutical distribution (15.41%) for the year 2024 [1] - Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received an invention patent certificate from the National Intellectual Property Administration for a compound with specific disulfide bond structures, which could provide new drug candidates in various disease treatment areas [1] Group 2 - On August 21, 2025, the net outflow of main funds for Wanbangde was 23.04 million yuan, accounting for 0.53% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 62.20 million yuan, representing 1.43% of the circulating market value [1]
万邦德:关于子公司获得发明专利的公告
Zheng Quan Ri Bao· 2025-08-21 13:42
Core Viewpoint - Wanbangde announced the receipt of an invention patent certificate from the National Intellectual Property Administration for a new compound and its preparation method, indicating potential advancements in pharmaceutical development [2] Company Summary - Wanbangde's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has received a patent for a "disulfide cyclic peptide compound and its preparation method and application," which may enhance its product offerings and competitive edge in the pharmaceutical industry [2]
万邦德:“一种二硫环肽化合物及其制备方法和应用”取得专利证书
Mei Ri Jing Ji Xin Wen· 2025-08-21 08:05
Group 1 - The core point of the article is that Wanbangde Pharmaceutical Holdings Group Co., Ltd. has received a patent for a new compound and its preparation method, which may enhance its competitive edge in the pharmaceutical industry [2] - Wanbangde's revenue composition for the year 2024 is as follows: 48.76% from pharmaceutical manufacturing, 32.21% from specialized equipment manufacturing and services, 15.41% from pharmaceutical distribution, and 3.62% from other industries [2]